scholarly article | Q13442814 |
P356 | DOI | 10.1517/14740338.2013.840583 |
P698 | PubMed publication ID | 24131458 |
P2093 | author name string | Changsu Han | |
Chi-Un Pae | |||
Prakash S Masand | |||
Sheng-Min Wang | |||
Soo-Jung Lee | |||
Ashiwn A Patkar | |||
P2860 | cites work | Analysis of suspected suicides using poison center data | Q23921390 |
QT interval and antidepressant use: a cross sectional study of electronic health records | Q24629713 | ||
Toxicology and overdose of atypical antipsychotics | Q28265894 | ||
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer | Q28320942 | ||
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder | Q31121208 | ||
Drug-induced prolongation of the QT interval | Q33151147 | ||
Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly | Q33158076 | ||
Assessing QT interval prolongation and its associated risks with antipsychotics. | Q33160123 | ||
Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study | Q33632295 | ||
Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose | Q33820358 | ||
National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 | ||
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. | Q34342685 | ||
Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose | Q34347727 | ||
Evaluation of a QT nomogram for risk assessment after antidepressant overdose. | Q34457439 | ||
Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort | Q34587359 | ||
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines | Q34590507 | ||
Antipsychotic-related QTc prolongation, torsade de pointes and sudden death | Q34730759 | ||
What Clinicians Should Know About the QT Interval | Q35112554 | ||
Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses | Q35827376 | ||
Clinical use of antidepressant therapy and associated cardiovascular risk | Q36184863 | ||
The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications | Q36512947 | ||
Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. | Q36946346 | ||
Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database | Q37152047 | ||
Electrophysiological changes of cardiac function during antidepressant treatment | Q37362668 | ||
A comparative study of non-fatal self-poisoning with antidepressants relative to prescribing in three centres in England | Q37623169 | ||
Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? | Q38022815 | ||
Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose | Q39095473 | ||
Sertindole causes distinct electrocardiographic T-wave morphology changes | Q39885611 | ||
The effect of sertindole on QTD and TPTE. | Q39915573 | ||
Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. | Q40283029 | ||
Tricyclic antidepressants in depressed patients with cardiac conduction disease | Q42224094 | ||
Torsade de Pointes Episodes under Treatment with Selective Serotonin Reuptake Inhibitors | Q42867714 | ||
Block of the human ether-a-go-go-related gene (hERG) K+ channel by the antidepressant desipramine | Q43138457 | ||
hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine | Q43487048 | ||
Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients | Q43690649 | ||
Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. | Q44710932 | ||
A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition | Q44717873 | ||
Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents | Q45711433 | ||
QTc intervals in drug poisoning patients with tricyclic antidepressants and selective serotonin reuptake inhibitors. | Q46024543 | ||
Exposure to antidepressant medications and suicide attempts in adult depressed inpatients | Q46645215 | ||
The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach | Q46819442 | ||
Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. | Q48681357 | ||
Use of an integrated mercury food web model for ecological risk assessment. | Q51196700 | ||
Reconciling the risk of QT interval prolongation in antidepressants. | Q54484056 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 197-205 | |
P577 | publication date | 2013-10-17 | |
P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
P1476 | title | Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram | |
P478 | volume | 13 |
Q47346313 | Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials |
Q33662939 | Effects of Escitalopram on Anxiety in Patients with Acute Coronary Syndrome: A Randomized Controlled Trial |
Q35754726 | Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder |
Q47604739 | Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement |
Q38536162 | Treating OCD: what to do when first-line therapies fail |
Search more.